Reclassification of early stage breast cancer into treatment groups by combining the use of immunohistochemistry and microarray analysis
| Autor: | Elizabeth Murray, Ettienne J. Myburgh, Colleen A. Wright, Martin Kidd, Fredrieka M. Pienaar, Maritha J. Kotze, Kathleen A. Grant |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty General Biochemistry Genetics and Molecular Biology lcsh:Social Sciences 03 medical and health sciences mammaprint 0302 clinical medicine Breast cancer Internal medicine medicine Oestrogen receptor lcsh:Social sciences (General) Stage (cooking) lcsh:Science lcsh:Science (General) MammaPrint Microarray analysis techniques business.industry molecular subtype BluePrint medicine.disease oestrogen receptor lcsh:H 030104 developmental biology 030220 oncology & carcinogenesis General Earth and Planetary Sciences Immunohistochemistry lcsh:Q lcsh:H1-99 General Agricultural and Biological Sciences business blueprint microarray lcsh:Q1-390 |
| Zdroj: | South African Journal of Science, Volume: 115, Issue: 3-4, Pages: 1-6, Published: APR 2019 South African Journal of Science, Vol 115, Iss 3/4 (2019) |
| ISSN: | 1996-7489 |
| DOI: | 10.17159/sajs.2019/5461 |
| Popis: | Immunohistochemistry (IHC) is routinely used to approximate breast cancer intrinsic subtypes, which were initially discovered by microarray analysis. However, IHC assessment of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) status, is a poor surrogate of molecular subtype. Therefore, MammaPrint/BluePrint (MP/BP) microarray gene expression profiling is increasingly used to stratify breast cancer patients into different treatment groups. In this study, ER/PR status, as reported by standard IHC and single-gene mRNA analysis using TargetPrint, was compared with molecular subtyping to evaluate the combined use of MP/BP in South African breast cancer patients. Pathological information of 74 ER/PR positive, HER2 negative tumours from 73 patients who underwent microarray testing, were extracted from a central breast cancer genomics database. The IHC level was standardised by multiplying the intensity score (0–3) by the reported proportion of positively stained nuclei, giving a score of 0–300. Comparison between mRNA levels and IHC determination of ER/PR status demonstrated a significant correlation (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|